DiagnaMed Announces DTC Eligibility of Its Common Shares in the United States
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB:DGNMF), a generative AI healthcare solutions company, is pleased to announce that its OTCQB-listed common shares under the symbol “DGNMF” are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. DTC Eligibility is expected to simplify the process of trading and enhance liquidity of DiagnaMed’s common shares in the United States. The Company’s shares began trading on the OTCQB on April 11, 2023.
Related news for (DGNMF)
- DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
- DiagnaMed Cancels Previously Announced Private Placement
- DiagnaMed Announces LIFE Offering of up to $650,000
- DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI
- DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI